Why the study?
Does a biomarker score combined with Wilkins's score improve the prediction of cardiac events in patients with mitral stenosis undergoing percutaneous balloon valvuloplasty?
Does a biomarker score combined with Wilkins's score improve the prediction of cardiac events in patients with mitral stenosis undergoing percutaneous balloon valvuloplasty?
A novel biomarker score combined with the echocardiographic Wilkins's score significantly improves the prognostic prediction of cardiac events after successful percutaneous balloon valvuloplasty in patients with mitral stenosis.
Answers are grounded in this paper and cite their sources.
May aid post-PBMV risk stratification in mitral stenosis; leaves open prospective validation of combined scoring.
Objective: We proposed a novel new insight independent score of Mitral Stenosis (MS) based on elevated biomarkers. Subjects and Methods: One hundred sixty-eight patients with MS candidate for Percutanous balloon valvuloplasty (PBMV) were included in the study. Brain Natriurectic Peptide (BNP), Tenascin-C (TN-C), copeptin and high-sensitive C-reactive protein (hs-CRP) were measured before PBMV. The cut-off value of each biomarker for prediction of systolic pulmonary artery pressure >50 mm Hg was calculated. Two points were given to a value cut-off value and one point if less. Summation of points gave the biomarkers score. Results: A biomarker score cut-off value 5.2 had a sensitivity of 83.6%, a specificity of 82.9% (AUC=0.85), in predicting cardiac events after successful PBMV. The Wilkins's score of 6.5 had a sensitivity of 73.5%, a specificity of 79.2% (AUC=0.80). The conjunction of Wilkins's score with biomarker score have higher predicting power (AUC=97%). The correlation co-efficient of biomarker score was (r=0.755), greater than that of the Wilkin's score (r=0.613). The combined biomarkers and Wilkins's score showed the strongest correlation with cardiac events (r=0.911). In multiple regression analysis, the regression co-efficient of biomarker score versus Wilkin's score was (0.595 versus 0.364), and the combined scores had the strongest powerful independent predictor of cardiac events (r=0.825). Conclusions: In patients with MS especially asymptomatic patients, biomarker risk score that included BNP, tenacin-c, copeptin and hs-CRP and, had a good correlation with clinical outcomes after successful PBMV, and the conjunction of the biomarkers score and Wilkin's score provided higher prognostic value.
No takes yet. Share an insight, caveat, or question.
Mahfouz et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: